AT-1501 + Tacrolimus
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Kidney Transplant Rejection
Conditions
Kidney Transplant Rejection
Trial Timeline
Aug 30, 2023 → Sep 25, 2025
NCT ID
NCT05983770About AT-1501 + Tacrolimus
AT-1501 + Tacrolimus is a phase 2 stage product being developed by Eledon Pharmaceuticals for Kidney Transplant Rejection. The current trial status is completed. This product is registered under clinical trial identifier NCT05983770. Target conditions include Kidney Transplant Rejection.
What happened to similar drugs?
20 of 20 similar drugs in Kidney Transplant Rejection were approved
Approved (20) Terminated (1) Active (0)
✅basiliximab + rabbit anti-thymocyte globulin + tacrolimus + alemtuzumab + mycophenolate mofetil + steroidsAstellas PharmaApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06126380 | Phase 2 | Recruiting |
| NCT05983770 | Phase 2 | Completed |
Competing Products
20 competing products in Kidney Transplant Rejection